GlassScriptPhysician profile
Regine M Pappas
NPI 1215921275
$48,287.69
in general payments reported to CMS, 2019-2025
32 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,712 · 2020: $6,528 · 2021: $9,392 · 2022: $8,091 · 2023: $2,492 · 2024: $2,569 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,088 · Food and Beverage: $7,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,087.50 |
| Food and Beverage | $7,477.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $16,121.53 | 2019-2021 | |
| Alcon Vision LLC | $6,868.47 | 2019-2025 | Rocklatan, Tryptyr, Hydrus Microstent |
| Nova Eye, INC. | $6,218.08 | 2025 | |
| Abbvie INC. | $5,977.75 | 2021-2025 | |
| Allergan, INC. | $5,102.89 | 2019-2022 | |
| Eyepoint US, INC. | $1,316.82 | 2019 | |
| Glaukos Corporation | $1,032.84 | 2024-2025 | Idosetr, Idose |
| New World Medical,INC. | $807.37 | 2019-2025 | Streamline, Kahook Dual Blade, Clearpath |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $610.04 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $558.12 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sight Sciences, INC. | $531.77 | 2021-2025 | Omni Surgical System |
| Lensar, INC. | $511.83 | 2024-2025 | Lensar Laser System |
| Sun Pharmaceutical Industries INC. | $394.16 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $382.68 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $317.76 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $271.80 | 2021-2022 | |
| Oyster Point Pharma, INC. | $248.40 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $183.22 | 2024-2025 | Vevye, Tobradex St, Natacyn |
| Amgen INC. | $179.23 | 2024-2025 | Tepezza |
| Dompe US, INC. | $154.55 | 2024 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $96.80 | 2021 | |
| Rayner Intraocular Lenses Limited | $73.03 | 2025 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Biotissue Holdings INC. | $47.82 | 2021-2024 | |
| Carl Zeiss Meditec, INC. | $42.04 | 2019 | |
| Iridex Corporation | $39.18 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $38.22 | 2019-2020 | |
| Halozyme INC | $37.41 | 2023-2025 | Hylenex Recombinant |
| Omeros Corporation | $37.06 | 2019 | |
| Thea Pharma INC. | $28.31 | 2023 | Iyuzeh |
| Ocular Therapeutix, INC. | $23.88 | 2025 | Dextenza |
| Shire North American Group INC | $20.73 | 2019 | |
| Akorn, INC. | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regine Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.